Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Weak
Website
N/ATelephone
61.2.9467.0400
Address
Crows Nest Level 3 20 Clarke Street Sydney, New South Wales (NSW) 2065
Description
SomnoMed Ltd. engages in the production and sale of devices for the oral treatment of sleep related disorders. Its products include SomnoDent, SomMorning Repositioner, SomnoBrux, SomTabs, and Sunrise Sleep Test. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded in 2004 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.19 - 0.75
Trade Value (12mth)
AU$7,133.00
1 week
0%
1 month
38%
YTD
-8.08%
1 year
-52.91%
All time high
4.34
EPS 3 yr Growth
450.300%
EBITDA Margin
1.20%
Operating Cashflow
-$4m
Free Cash Flow Return
-10.10%
ROIC
-20.60%
Interest Coverage
0.40
Quick Ratio
1.30
Shares on Issue (Fully Dilluted)
121m
HALO Sector
Healthcare
Next Company Report Date
29-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
24 July 24 |
Quarterly Activities Report
×
Quarterly Activities Report |
24 July 24 |
Quarterly Cashflow Report
×
Quarterly Cashflow Report |
01 July 24 |
Notification regarding unquoted securities - SOM
×
Notification regarding unquoted securities - SOM |
01 July 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
01 July 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
28 June 24 |
Notification regarding unquoted securities - SOM
×
Notification regarding unquoted securities - SOM |
27 June 24 |
Results of Meeting
×
Results of Meeting |
20 May 24 |
Notice of Extraordinary General Meeting
×
Notice of Extraordinary General Meeting |
20 May 24 |
Proxy Form
×
Proxy Form |
13 May 24 |
Repayment of Epsilon facility
×
Repayment of Epsilon facility |
10 May 24 |
Change in substantial holding
×
Change in substantial holding |
10 May 24 |
Change in substantial shareholding from AEF
×
Change in substantial shareholding from AEF |
09 May 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
08 May 24 |
Application for quotation of securities - SOM
×
Application for quotation of securities - SOM |
08 May 24 |
Change in substantial holding
×
Change in substantial holding |
08 May 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
08 May 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
08 May 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
08 May 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
03 May 24 |
Completion of retail component of Entitlement Offer
×
Completion of retail component of Entitlement Offer |
01 May 24 |
Notification of cessation of securities - SOM
×
Notification of cessation of securities - SOM |
29 April 24 |
Quarterly Cashflow Report
×
Quarterly Cashflow Report |
29 April 24 |
Quarterly Activities Report
×
Quarterly Activities Report |
18 April 24 |
Change in substantial shareholding from AEF
×
Change in substantial shareholding from AEF |
18 April 24 |
Change in substantial holding
×
Change in substantial holding |
16 April 24 |
Replacement Prospectus
×
Replacement Prospectus |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.